Episode 3.2: Ranting About Rituximab in Acute Lymphoblastic Leukemia
WolverHeme Happy Hour
00:00
Retuxemab and the EFS Benefit
In practice, 30% of people are switching to rewinnia because of allergic reactions. In a large cooperative group study that shows that... I don't even know what the switch rates are here, but... This is any grade. Any grade reactions is only 8%. Only 8%. So at max, only 8% of patients in this study would switch. But again, these are only grade one or two. These weren't anaphylaxis, these weren't high-grades. And so probably only a couple of percent of patients switched to reWinnia in this study. It's not wild. It's wild.
Transcript
Play full episode
